

Response to Reviewer 1 Comments

Dear reviewer,

Thank you very much for taking the time to review the manuscript, as well as for your kind and excellent suggestions. Regarding your contributions:

Comment 1. *“Novelty. There are similar topics published recently. Please consider adding these references and try to improve the novelty. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data. PMID: 36713515. Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. PMID: 36809408”.*

- **Response 1.** Thank you for pointing this out. We agree with this comment. Therefore, after careful consultation of both articles, important information was obtained from both and included in the new version of the manuscript.

Comment 2. *“Detailed Discussion of Mechanisms: Expanding on the potential mechanisms behind the observed phenomenon of VLL could provide a deeper understanding”.*

- **Response 2.** Once again, thank you for pointing this out. We agree with this comment. We revised the available data regarding the potential mechanisms behind ICI-induced VLL and included new information, namely important and recent data regarding inflammatory cells involved in its pathophysiology.

Comment 3. *“Clinical Practice Implications: A section discussing how these findings might influence future clinical practices in NSCLC treatment would add practical value”.*

- **Response 3.** We also agree with this comment. We cautiously included a new section named “Possible Clinical Practice Implications”.

Once again, thank you for the dedicated time.